Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - disodium edetate, quantity: 30 mg/ml - injection, concentrated - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, cons

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

United States - English - NLM (National Library of Medicine)

edetate disodium, anhydrous (unii: 8nlq36f6mm) (edetic acid - unii:9g34hu7rv0) - injection, solution - endrate (edetate disodium injection, usp) is indicated in selected patients for the emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity. endrate (edetate disodium injection, usp) is contraindicated in anuric patients. it is not indicated for the treatment of generalized arteriosclerosis associated with advancing age.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - chromium(51cr) edetate, quantity: 8 mbq/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; chromium edetate - indications as at 17 sep 02 : determination of glomerular filtration rate in the assessment of renal function.

United States - English - NLM (National Library of Medicine)

bausch health us, llc - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium 200 mg in 1 ml - edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - samarium (153sm), quantity: 2 gbq/ml - injection - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; ethylenediaminetetramethylenephosphonic acid monohydrate; calcium hydroxide - indications: quadramet is indicated for the relief of bone pain in patients with painful osteoblastic skeletal metastases as indicated by positive bone scan. the presence of bone metastases should be confirmed prior to therapy.

United States - English - NLM (National Library of Medicine)

emergent devices inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 2 mg in 0.1 ml - narcan nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. narcan nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. narcan nasal spray is not a substitute for emergency medical care. limitations of use: restrict prescription of narcan nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. narcan nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. risk summary the limited available data on naloxone use in pregnant women are not sufficient to inform a drug-associated risk. however, there are clinical considerations [see clinical considerations] . in animal reproduction studies, no embryotoxic or teratogenic ef

European Union - English - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuclide imaging - therapeutic radiopharmaceuticals - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.